in type 2 diabetes. Endocrinol Metabol Clinics N Am 30:935–982, 2001 6. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, UKPDS Study Group:Sulfonylurea inadequacy: efﬁcacy of addi-tion of insulin over 6 years in patientswith type 2 diabetes in the U.K. Prospec-tive Diabetes Study (UKPDS 57). 25:330–336, 2002 7. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS: Racial and ethnic dif-ferences in glycemic control of adults withtype 2 diabetes. Diabetes Care 22:403– 408, 1999 8. Inzucchi SE: Oral antihyperglycemic ther- apy for type 2 diabetes. JAMA 287:360– 372, 2002 9. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glu-cose-lowering and insulin-sensitizing ac-tions of exendin-4: studies in obesediabetic ( ob/ob, db/db ) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys(Macaca mulatta ).Diabetes 48:1026–1034, 1999 10. Parkes DG, Pittner R, Jodka C, Smith P,